Asston Pharmaceuticals Ltd
Incorporated in 2019, Asston Pharmaceuticals Ltd is in the business of manufacturing pharmaceutical products.[1]
- Market Cap ₹ 119 Cr.
- Current Price ₹ 108
- High / Low ₹ 126 / 60.0
- Stock P/E 30.2
- Book Value ₹ 45.6
- Dividend Yield 0.00 %
- ROCE 17.0 %
- ROE 15.7 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Earnings include an other income of Rs.6.07 Cr.
- Company has high debtors of 524 days.
- Working capital days have increased from 258 days to 434 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 9.60 | 6.54 | 16.03 | 25.04 | 25.47 | |
| 9.96 | 5.02 | 12.21 | 19.60 | 25.99 | |
| Operating Profit | -0.36 | 1.52 | 3.82 | 5.44 | -0.52 |
| OPM % | -3.75% | 23.24% | 23.83% | 21.73% | -2.04% |
| 0.96 | 0.65 | 0.25 | 0.57 | 6.07 | |
| Interest | 0.43 | 0.72 | 0.76 | 0.95 | 0.63 |
| Depreciation | 0.01 | 0.04 | 0.06 | 0.04 | 0.32 |
| Profit before tax | 0.16 | 1.41 | 3.25 | 5.02 | 4.60 |
| Tax % | 31.25% | 25.53% | 25.23% | 23.11% | 15.87% |
| 0.11 | 1.06 | 2.43 | 3.85 | 3.87 | |
| EPS in Rs | 1.57 | 15.14 | 31.00 | 6.14 | 4.55 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 57% |
| TTM: | 2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 55% |
| TTM: | 4% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 8% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 28% |
| 3 Years: | 26% |
| Last Year: | 16% |
Balance Sheet
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 0.70 | 0.70 | 0.78 | 6.27 | 8.51 |
| Reserves | 0.23 | 1.29 | 6.40 | 4.76 | 30.35 |
| 3.31 | 5.24 | 6.82 | 7.26 | 5.10 | |
| 5.25 | 6.46 | 6.70 | 9.83 | 7.69 | |
| Total Liabilities | 9.49 | 13.69 | 20.70 | 28.12 | 51.65 |
| 0.92 | 1.13 | 0.97 | 0.96 | 10.69 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 8.57 | 12.56 | 19.73 | 27.16 | 40.96 | |
| Total Assets | 9.49 | 13.69 | 20.70 | 28.12 | 51.65 |
Cash Flows
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| -1.19 | -0.32 | -3.97 | -0.03 | -10.18 | |
| 0.00 | -0.91 | -0.01 | 0.73 | -9.91 | |
| 1.29 | 1.21 | 3.86 | -0.51 | 21.18 | |
| Net Cash Flow | 0.10 | -0.01 | -0.12 | 0.19 | 1.09 |
| Free Cash Flow | -1.19 | -0.57 | -3.98 | 0.68 | -20.24 |
| CFO/OP | 322% | -20% | -92% | -0% | 1,500% |
Ratios
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 243.33 | 480.53 | 380.71 | 357.86 | 524.07 |
| Inventory Days | 27.24 | 204.29 | 53.91 | 18.59 | 16.14 |
| Days Payable | 246.78 | 754.51 | 217.50 | 156.94 | 120.76 |
| Cash Conversion Cycle | 23.79 | -69.70 | 217.12 | 219.50 | 419.45 |
| Working Capital Days | -12.17 | 43.53 | 162.80 | 176.96 | 434.22 |
| ROCE % | 37.14% | 37.78% | 36.61% | 16.96% |
Insights
In beta| Mar 2023 | Mar 2024 | May 2025 | |
|---|---|---|---|
| Export Revenue (% of Total Sales) % |
|
||
| Pharmaceuticals Sales (% of Total Sales) % |
|||
| Sierra Leone Revenue (% of Total Sales) % |
|||
| Top 5 Customer Concentration (% of Revenue) % |
|||
| Total Production Volume MT |
|||
| Number of Registered Product Brands count |
|||
| Order Book USD |
|||
Extracted by Screener AI
Documents
Announcements
-
Reg. 34 (1) Annual Report.
- Asston Pharmaceuticals submitted FY2025-26 annual report; notes IPO, July 2025 listing, and new plant production start.
-
Notice Of 7Th Annual General Meeting
- 7th AGM on 29 Sep 2026; approve FY26 accounts, auditors, and director remuneration increases.
-
Announcement under Regulation 30 (LODR)-Allotment
- Board approved preferential allotment of 24,10,431 shares at Rs.115 to 15 investors on 05 Sep 2026.
-
Board Meeting Outcome for Allotment Of 24,10,431 Equity Shares Via Preferential Allotment
- Board approved preferential allotment of 24,10,431 shares at Rs.115 to 15 investors on 5 September 2026.
- Fixing Record Date
Business Overview:[1]
APL offers pharmaceutical products in the form of Tablet, Capsules, Syrup, Sachet and Injection (LVP and SVP). The company has WHO GMP approved manufacturing units for manufacturing
the entire products range and also has
a tie up with a NABL Accredited Laboratory.